Diagnosis of polycythaemia

It is generally accepted that an adult has some form of polycythaemia if there is a persistently raised haematocrit (men > 0.51, women > 0.48) in blood samples taken without venous occlusion. Precise diagnosis of the type of polycythaemia is necessary not only from the point of view of prognosis and treatment but also as a stimulus to a better understanding of the aetiology, pathogenesis, molecular, and genetic basis of these disorders.

Red cell mass measurement is fundamental to the diagnostic pathway of polycythaemias. Red cell mass values are best expressed as a percentage variation from that predicted for a normal individual of the same height and weight. Expression as ml/kg total body weight is not recommended as it does not consider that fatty tissue is less vascular than lean tissue. A red cell mass 25% or more above the mean normal value for that patient is deemed raised and constitutes an absolute polycythaemia, while patients with raised packed cell volume (PCV) values, but raised and above the mean normal value for that patient is deemed vascular than lean tissue. A red cell mass 25% or more will allow an estimate of spleen size. Patients with an absolute polycythaemia and palpable splenomegaly (without other cause) fulfil the criteria for the diagnosis of PV, but in those without a palpable spleen who nevertheless appear to have some splenic enlargement by ultrasound, the likelihood of PV is strengthened and that of secondary polycythaemia weakened.

While measurement of serum erythropoietin is now both relatively simple and reliable, it has proved less useful than hoped in distinguishing different types of polycythaemia. Only about half of patients with secondary polycythaemia have raised erythropoietin, and about two thirds of those with PV have a reduced concentration. However, it is one of the newer tests, in addition to spleen sizing and karyotyping, that have helped to modernise the diagnostic criteria of PV.

The clonal nature of PV cell proliferation is well established. The pluripotent nature of the bone marrow cell concerned results in raised neutrophils (> 10 × 10^9/l) and/or platelets (> 400 × 10^9/l) as well as red cells in the peripheral blood of a large proportion of patients. Except in the small number of patients (15%) with PV who have an easily identifiable cytogenetic abnormality (such as 20q−), clonality is difficult to demonstrate. Currently it depends on research techniques that identify X chromosome inactivation patterns and therefore applies only to women. Bone marrow examination is useful not only for karyotyping but also to assess histology that can show characteristic changes in PV. However, standardised objective criteria of histological assessment are not yet established for precise diagnostic use.

Another expression of the abnormal proliferating clone in PV is its behaviour in culture. Evidence that red cell precursors in the peripheral blood will grow in serum containing culture media to form colonies without the addition of further erythropoietin (endogenous erythroid colonies) has been widely assessed as a potentially useful test to distinguish PV from other polycythaemias. This is not a routine procedure and must be standardised in each laboratory to provide a discriminatory test. Further elucidation of abnormal responses of the PV clone to erythropoietin and other growth factors may permit more reliable tests to be developed as well as perhaps enabling the subdivision of PV into types with differing genetic constitutions.

The term idiopathic erythrocytosis (benign or pure erythrocytosis) is by definition used for patients where, despite adequate investigation, no cause for absolute polycythaemia has been established. This is a heterogenous
group at present, but with increasing understanding of pathogenesis some will be found to have identifiable congenital or acquired abnormalities of erythropoiesis.\textsuperscript{11} Some individuals with only mildly raised red cell mass probably represent a physiological extreme, while others may be at an early stage of evolution into PV or some clearly recognisable secondary polycythaemia.

Apparent polycythaemia (Geisbock's syndrome, stress, pseudo or relative polycythaemia) is defined as raised PCV and normal red cell mass. The aetiology is imprecise as in idiopathic erythrocytosis. Approximately one third of patients have a reduced plasma volume. Some are probably physiological variants showing a red cell mass near the upper normal limit for that patient’s height and weight combined with plasma volume near the lower limit. Others may be evolving into an absolute polycythaemia with causes as previously described. In the remainder, various associations have been observed, particularly with hypertension, obesity, smoking, and arterial hyoxaemia, although the mechanisms are not yet clear.\textsuperscript{12} In about one third of these patients, PCV tends to revert to normal over time. Ideally, individuals with apparent polycythaemia should undergo the rigorous investigation carried out in patients with absolute polycythaemia. In practice, personal and financial considerations generally limit investigation of patients with apparent polycythaemia to a full blood count, biochemistry screen, arterial oxygen saturation, carbon monoxyaemoglobin concentration, and an abdominal ultrasound.

M MESSINEZY
T C PEARSON

Early diagnosis of myocardial infarction: why measure cardiac enzymes?

A typical district general hospital will see approximately 5000 patients each year in whom a diagnosis of acute coronary syndrome is suspected. This will include not only patients with unstable angina or acute myocardial infarction (AMI) but also patients presenting with chest pain of unknown cause, sudden onset of breathlessness, rhythm disturbance or worsening ischaemic heart disease. Is rapid biochemical diagnosis required?

The decision to admit to hospital and whether the patient will be placed in the coronary care unit (CCU) or a general ward/low dependency facility will depend on the initial clinical assessment plus electrocardiography (ECG). Both of these are known to be imperfect approaches—11.8% of patients with AMI are sent home from the accident and emergency department\textsuperscript{1} and patients without coronary artery disease inappropriately occupy 25% of CCU beds. Using postmortem examination as the gold standard, biochemical diagnosis of AMI has been shown to be superior to ECG.\textsuperscript{2} Although the sensitivity of ECG is only 75% on presentation, ST segment elevation has 99.7% specificity for AMI, identifying the group that will have maximum benefit from thrombolytic treatment.\textsuperscript{3} ECG criteria can be used to select for thrombolyis patients who present with ST segment elevation or bundle branch block. Giving thrombolytic agents on the basis of clinical features alone will confer no benefit in the absence of ST segment elevation and can result in additional morbidity and mortality in the patient both with and without ischaemic heart disease. For example, dissecting aneurysm can present with chest pain and thrombolyis in such cases has a spectacular effect on outcome. Widespread use of thrombolytic treatment in the absence of ECG data by paramedic staff cannot be justified.

Most cases do not have a clear cut presentation. An audit of cases presenting to the Mayday Hospital (Thornton Heath, Surrey, UK) who had cardiac enzyme analysis showed that (with diagnosis based on WHO criteria for AMI) only 9.6% of patients presenting with chest pain had ST segment elevation on presentation. On the basis of biochemical testing a further 2.4% were diagnosed with non-Q wave AMI and 7.8% had biochemical changes characteristic of myocardial damage. Sixty six per cent of cases had a final diagnosis of stable angina or non-ischaemic chest pain.

Clearly the ECG is not a diagnostic but a management tool that should be used to select patients for thrombolytic treatment. This constitutes the minority of patients investigated. Most will require biochemical confirmation or exclusion of AMI. Identification of patients without ECG changes who have either a non-Q wave AMI or unstable angina with minor myocardial damage is important. These patients have a short term mortality that exceeds that of patients with Q wave AMI, and they require early intervention. The ECG has superior diagnostic sensitivity to all currently available biochemical markers in samples taken on admission.\textsuperscript{4} This is because of the kinetics of release of biochemical markers from ischaemic tissue and the problem of single measurement compared with a population based reference range. Early diagnosis of myocardial infarction can be achieved by serial measurement of myoglobin,\textsuperscript{5} creatine kinase (CK)\textsuperscript{6} or its MB isoenzyme (CK-MB).\textsuperscript{7} Diagnosis can be complete within 24 hours of presentation. By using a combination of a short time

---

window marker plus a long time window marker, measured serially in the same patient, the diagnostic time window can be reduced to as little as four hours from admission. The strategy in the UK for biochemical diagnosis is usually based around a protocol of a combination of daily measurement of CK, aspartate transaminase (AST), and lactate dehydrogenase (LDH). The diagnostic superiority of CK-MB has been established both by clinical studies and rigorous statistical comparison with other markers. It is considered the standard marker in Europe and North America. The technology for rapid, accurate, and precise mass measurement of CK-MB is available in the UK and is the method of choice for confirmation or exclusion of AMI by conventional criteria. However, the cardiac enzyme strategy in most hospitals is both diagnostically inadequate and does not provide information within a useful time frame for medical decision making. Two other factors combine to make the present situation unacceptable.

The first is the development of assays for the cardiac specific marker proteins troponin T and troponin I. These markers are 100% sensitive and specific for cardiac damage. They allow prognostic risk stratification for patients with a diagnosis of AMI and unstable angina. The information cannot be obtained from CK-MB measurement or ECG. The cardiac specific markers troponin T and troponin I will replace CK-MB as they allow diagnosis to be complete within 12 hours of admission, are more sensitive and specific, and have prognostic value. They will become the gold standard for diagnosis.

The second is the evolution of point of care testing (POCT). Rapid quantitative analysis of CK can be performed reliably on whole blood using small bench-top analysers. POCT devices are currently available for the detection of myoglobin, CK-MB, troponin T, and troponin I. These devices can be used in the emergency department or the CCU to produce results within 20 minutes from first blood sampling. Although these devices are currently semi-quantitative, quantitative analysis of cardiac markers with measurement on whole blood is already undergoing clinical trials.

The rapid provision of an accurate biochemical diagnosis is not required for patients with characteristic ECG changes, but is needed to prevent inappropriate discharge of those with cardiac damage, and to expedite the discharge of those without active ischaemic heart disease. Thus, decision-making will initially divide patients into those with and without ST segment elevation. The former require thrombolysis and admission to the CCU. Those without ST segment elevation can be assessed rapidly by enzymatic testing.

The issue of which troponin is better can be debated with arguments over specificity in renal failure. Troponin T has been more extensively clinically validated while direct comparison of troponin T and I suggests that troponin T is the more sensitive in the cardiac group, the clinically most significant group of patients.

In conclusion, cardiac enzymes are integral to the diagnosis and management of patients in whom acute coronary syndromes are suspected. They are not needed to diagnose the minority, who present with ST segment elevation, but they are essential for the early differential diagnosis of those at highest and lowest risk. These patients can be diagnosed by biochemical tests alone, to expedite management decisions. Cardiac troponin measurement is the most clinically effective test, offering prognostic information to the clinician unavailable by other investigations, and should be part of the modern testing strategy. The role of biochemical testing is as part of a structured decision making protocol providing accurate and timely information that can be used to guide patient management.

If the test results are not used, then biochemical testing becomes an irrelevance. The current antediluvian practice of offering daily measurements of CK, AST, and LDH serves only to provide a postscript to the discharge summary or death, whichever comes first, and should be abandoned in favour of an integrated approach using outcome related tests (troponin T or I) to alter patient management directly. There are financial benefits in terms of reduction of patient episode cost while accurate diagnosis from modern tests will aid prognostic decision making. Converting this into routine clinical practice is a challenge both for the laboratory and the clinician.

P O COLLINS
Consultant Chemical Pathologist, Mayday Hospital, London Road, Thornton Heath, Surrey CR7 7YE, UK
email: poctrop@poctrop.demon.co.uk


19 Collinson PO. To T or not to T, that is the question. *Clin Chem* 1997;43:421-3.


Early diagnosis of myocardial infarction: why measure cardiac enzymes?

P O Collinson

*J Clin Pathol* 1998 51: 2-4
doi: 10.1136/jcp.51.1.2

Updated information and services can be found at:
http://jcp.bmj.com/content/51/1/2.citation

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/